SIVA1 Antibody

What is the SIVA1 protein and what are its primary biological functions?

SIVA1, also known as CD27BP, is a 19 kDa apoptosis-inducing factor comprising approximately 175 amino acids. It functions primarily as a pro-apoptotic protein that induces CD27-mediated apoptosis through caspase-dependent mitochondrial pathways . SIVA1 interacts with BCL-XL and inhibits its anti-apoptotic activity, thereby sensitizing cells to UV radiation-induced apoptosis . Additionally, SIVA1 inhibits NF-κB activation while promoting T-cell receptor-mediated apoptosis .

Beyond its apoptotic functions, SIVA1 plays critical roles in:

• DNA damage response through interactions with PCNA and the ubiquitin ligase RAD18

• Regulation of the balance between NFκB and JNK signaling pathways

• Inhibition of proliferation, migration, and invasion in certain cancer cell types, such as ovarian cancer

SIVA1 antibodies require specific storage conditions to maintain their activity and specificity:

• Temperature: Store at -20°C for long-term preservation (stable for up to one year)

• Short-term storage (up to three months) at 4°C is possible for some formulations

• Buffer composition: Typically provided in PBS with 0.02% sodium azide and sometimes with 50% glycerol at pH 7.3

• Aliquoting: For antibodies without stabilizers like glycerol, aliquoting is recommended to avoid repeated freeze-thaw cycles

• Freeze-thaw cycles: Avoid repeated freeze-thaw cycles as they can degrade antibody quality and reduce binding efficiency

Some formulations (20 μl sizes) may contain 0.1% BSA as a stabilizer . Always check the manufacturer's recommendations for specific storage requirements.

What are the optimal protocols for detecting SIVA1 in different cellular compartments?

SIVA1 detection requires specific methodological approaches depending on the cellular compartment being studied:

Nuclear SIVA1 Detection:

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.2% Triton X-100 for 10 minutes

• Block with 3% BSA in PBS for 1 hour

• Incubate with primary SIVA1 antibody at 4 μg/ml concentration overnight at 4°C

• Wash 3× with PBS containing 0.1% Tween-20

• Incubate with fluorescently labeled secondary antibody for 1 hour at room temperature

• Counterstain nuclei with DAPI

Cytoplasmic/Mitochondrial SIVA1 Detection:
Because SIVA1 interacts with mitochondrial proteins like BCL-XL, detection of its mitochondrial localization requires co-localization studies with mitochondrial markers. Use gentle detergent permeabilization (0.1% saponin) to preserve mitochondrial integrity during immunofluorescence studies .

What validation steps should be performed when using a new SIVA1 antibody?

Proper validation is essential when using a new SIVA1 antibody to ensure specific detection of the target protein:

• Positive control tissues/cell lines: Use cell lines known to express SIVA1, such as HeLa, HEK293T, MCF-7, or immune cells from thymus and spleen

• Knockdown validation:

  • Transfect cells with SIVA1-specific siRNAs (two independent siRNAs recommended)

  • Confirm knockdown efficiency via Western blot or qPCR

  • Compare antibody signal between control and SIVA1-depleted samples

• Recombinant protein detection:

  • Test antibody against purified recombinant SIVA1 protein

  • Compare with SFB-tagged or Myc-tagged SIVA1 protein expression

• Cross-reactivity assessment:

  • Evaluate potential cross-reactivity with related proteins

  • Include negative control proteins (e.g., Morc3 has been used as a negative control)

• Immunoprecipitation validation:

  • Confirm interaction partners of SIVA1 (e.g., PCNA, CD27, BCL-XL, XIAP)

  • Verify antibody's ability to immunoprecipitate native protein complexes

How does SIVA1 contribute to DNA damage response pathways?

SIVA1 plays a critical role in the DNA damage response, particularly after UV-induced damage:

• PCNA binding and regulation:

  • SIVA1 was identified as a PCNA-binding protein through tandem affinity purification and mass spectrometry analysis

  • This interaction is DNA damage-independent and exists in multiple cell lines including HeLa and HEK293T

  • SIVA1 forms part of the machinery that helps cells cope with DNA damage during replication

• RAD18 direction for PCNA ubiquitination:

  • SIVA1 acts as an accessory protein for the E3 ubiquitin ligase RAD18

  • It facilitates RAD18-mediated monoubiquitination of PCNA following UV damage

  • This modification is crucial for translesion DNA synthesis (TLS)

• Polη recruitment:

  • SIVA1 is required for efficient recruitment of DNA polymerase η (Polη) to sites of UV-induced DNA damage

  • Cells depleted of SIVA1 show defects in Polη recruitment, leading to increased UV sensitivity

  • The mechanism involves SIVA1-dependent PCNA monoubiquitination, which serves as a platform for Polη binding

Experimental evidence shows that SIVA1 knockdown cells exhibit significantly elevated sensitivity to UV radiation but display little sensitivity to other DNA-damaging agents like mitomycin C (MMC) and hydroxyurea (HU), suggesting a specific role in UV damage response .

What methods can be used to study SIVA1's role in mutation suppression?

SIVA1 plays an important role in mutation suppression, particularly following UV damage. The following methodological approaches can be used to investigate this function:

• Shuttle vector mutagenesis assay:

  • Use the pZ189 shuttle vector system to measure mutation frequency

  • The protocol involves:
    a) Transfecting UV-irradiated shuttle vectors into control or SIVA1-depleted cells
    b) Allowing cells to repair the damage
    c) Extracting and amplifying the plasmids
    d) Analyzing mutation frequency by screening for supF gene mutations

  • Results show dramatically elevated mutation frequencies in SIVA1-depleted cells

• Co-depletion experiments:

  • Perform siRNA-mediated knockdown of SIVA1 alone or in combination with Polη

  • Compare mutation frequencies between single and double knockdowns

  • This approach helps determine whether SIVA1 and Polη operate in the same pathway

• UV sensitivity assays:

  • Expose SIVA1-depleted and control cells to varying doses of UV radiation

  • Measure cell survival using colony formation assays or viability tests

  • This provides functional evidence of SIVA1's role in UV damage tolerance

• Immunofluorescence-based repair assays:

  • Monitor the recruitment of repair proteins to sites of localized UV damage

  • Quantify the accumulation of DNA repair factors like Polη at damage sites

  • Compare between control and SIVA1-depleted cells

These methods collectively provide comprehensive insights into how SIVA1 contributes to genomic stability and mutation suppression following DNA damage.

How does SIVA1 function in different cancer types, and what methodologies help elucidate these roles?

SIVA1 exhibits context-dependent roles in cancer biology, functioning differently across cancer types:

Ovarian Cancer:

• SIVA1 acts as a tumor suppressor in ovarian cancer

• Overexpression of SIVA1 inhibits proliferation, promotes apoptosis, and suppresses migration and invasion of ovarian cancer cells

• Mechanism involves facilitation of Stathmin phosphorylation and polymerization of α-tubulin

Methodological approaches for studying SIVA1 in cancer:

• Stable overexpression system:

  • Generate stable cell lines overexpressing SIVA1 using lentiviral vectors

  • Validate expression levels via Western blot and qPCR

  • Compare phenotypes with control cells expressing empty vectors

• Functional assays:

  • Proliferation: MTT or BrdU incorporation assays

  • Apoptosis: Annexin V/PI staining, caspase activity assays

  • Migration: Wound healing/scratch assays

  • Invasion: Transwell invasion assays with Matrigel coating

• Mechanistic studies:

  • Examine interactions with cytoskeletal regulators (e.g., Stathmin)

  • Analyze post-translational modifications of target proteins

  • Investigate effects on microtubule dynamics through α-tubulin polymerization assays

What are the most effective immunohistochemistry protocols for detecting SIVA1 in cancer tissue samples?

For effective immunohistochemical detection of SIVA1 in cancer tissues, the following optimized protocol is recommended:

• Tissue preparation:

  • Fix tissues in 10% neutral-buffered formalin for 24-48 hours

  • Process and embed in paraffin

  • Section at 4-5 μm thickness

• Antigen retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0)

  • Pressure cook for 15-20 minutes

  • Cool to room temperature gradually

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% hydrogen peroxide for 10 minutes

  • Block non-specific binding with 5% normal serum

  • Incubate with primary SIVA1 antibody at 1:100-1:200 dilution overnight at 4°C

  • Apply appropriate biotinylated secondary antibody for 30 minutes

• Detection and visualization:

  • Use avidin-biotin complex (ABC) or polymer detection systems

  • Develop with DAB substrate

  • Counterstain with hematoxylin

  • Dehydrate, clear, and mount

• Controls and validation:

  • Include positive control tissues (thymus, spleen)

  • Use isotype control antibodies as negative controls

  • Consider dual immunofluorescence with established markers to confirm specificity and localization

This protocol has been optimized based on available literature and standard immunohistochemical practices for detecting SIVA1 in various cancer tissues.

How can researchers investigate SIVA1's role in NFκB and JNK signaling pathways?

SIVA1 differentially modulates NFκB and JNK signaling pathways, shifting the balance toward enhanced JNK activation and promoting apoptosis . Researchers can investigate these roles using the following approaches:

• Reporter gene assays:

  • Transfect cells with NFκB or AP1 (JNK target) reporter constructs

  • Co-transfect with SIVA1 expression vectors and pathway activators (XIAP, TAK1-TAB1, or TNFα)

  • Measure luciferase activity to quantify pathway activation

  • Control experiments should include pathway inhibitors and empty vectors

• Protein complex analysis:

  • Co-immunoprecipitation to detect ternary complex formation between SIVA1, XIAP, and TAK1

  • Use both overexpressed tagged proteins and endogenous proteins

  • Western blot analysis with specific antibodies to confirm interactions

  • Consider size-exclusion chromatography to analyze complex formation

• JNK activation analysis:

  • Stimulate cells with TNFα after SIVA1 overexpression or knockdown

  • Monitor JNK phosphorylation over time (0-120 minutes) by Western blotting

  • Compare activation kinetics between control and SIVA1-modified cells

  • Use JNK inhibitors to confirm specificity of the observed effects

• Ubiquitination assays:

  • Analyze SIVA1 ubiquitination by XIAP through in vivo and in vitro approaches

  • Detect lysine-48-linked polyubiquitination using specific antibodies

  • Examine the role of XIAP's ubiquitin ligase activity using RING domain mutants

  • Study the effect of ubiquitination on SIVA1's signaling functions

These methodologies enable comprehensive analysis of how SIVA1 balances NFκB and JNK signaling to regulate cellular fate decisions.

What approaches can be used to study the interaction between SIVA1 and the translesion synthesis machinery?

SIVA1's interaction with the translesion synthesis (TLS) machinery represents an important aspect of its function in DNA damage tolerance. Researchers can employ these methodologies to study these interactions:

• Protein interaction mapping:

  • Define the domains of SIVA1 that interact with PCNA and RAD18

  • Generate truncation and point mutants of SIVA1

  • Perform co-immunoprecipitation or pull-down assays with purified proteins

  • Use techniques like yeast two-hybrid assays for domain mapping

• Live-cell imaging of DNA damage sites:

  • Express fluorescently tagged SIVA1 and TLS components (e.g., PCNA, Polη)

  • Induce localized DNA damage using UV laser microirradiation

  • Track recruitment kinetics using real-time confocal microscopy

  • Compare wild-type versus mutant proteins to identify functional domains

• In vitro reconstitution of PCNA ubiquitination:

  • Purify recombinant components (PCNA, RAD18, UBC13, SIVA1)

  • Perform in vitro ubiquitination assays with purified proteins

  • Analyze products by Western blotting with anti-ubiquitin antibodies

  • Test the effects of SIVA1 addition or omission on reaction efficiency

• Chromatin immunoprecipitation (ChIP):

  • Perform ChIP assays after UV damage to detect SIVA1 recruitment to chromatin

  • Co-immunoprecipitate SIVA1 with damaged DNA

  • Analyze co-localization with PCNA, RAD18, and other TLS factors

  • Use sequential ChIP (re-ChIP) to detect protein complexes at damage sites

These approaches collectively provide mechanistic insights into how SIVA1 contributes to translesion synthesis and maintains genomic integrity after DNA damage.

Why might SIVA1 antibodies show inconsistent results across different experimental systems?

Several factors can contribute to inconsistent results when using SIVA1 antibodies:

• Protein expression variability:

  • SIVA1 expression levels vary across tissues and cell types

  • Expression is elevated in immune system organs like thymus and spleen

  • Expression may be altered in pathological conditions such as acute ischemic injury

  • Solution: Include positive control samples with known SIVA1 expression

• Post-translational modifications:

  • SIVA1 undergoes ubiquitination by XIAP

  • Other potential modifications might affect epitope recognition

  • Solution: Use antibodies targeting different regions of SIVA1 to confirm results

• Antibody specificity issues:

  • Cross-reactivity with related proteins

  • Batch-to-batch variability in polyclonal antibodies

  • Solution: Validate antibodies using knockdown experiments and recombinant proteins

• Technical variables:

  • Fixation methods affecting epitope accessibility (particularly important for IHC/ICC)

  • Buffer composition influencing antibody-antigen interactions

  • Solution: Optimize fixation and antigen retrieval conditions for each application

• Protein interactions masking epitopes:

  • SIVA1 forms complexes with multiple partners (PCNA, XIAP, TAK1, BCL-XL)

  • These interactions may mask antibody epitopes

  • Solution: Use denaturing conditions for Western blots; optimize extraction methods

What are the recommended controls and validation steps for studying SIVA1-protein interactions?

When studying SIVA1 interactions with other proteins, the following controls and validation steps are essential:

• Reciprocal co-immunoprecipitation:

  • Immunoprecipitate with antibodies against both SIVA1 and the putative interacting protein

  • Western blot to detect both proteins in each immunoprecipitate

  • This confirms the interaction is detectable regardless of which protein is targeted

• Domain mapping controls:

  • Use truncated or mutant versions of both SIVA1 and interacting proteins

  • Identify specific domains required for the interaction

  • For example, interactions with XIAP map to the RING domain of XIAP and multiple domains of SIVA1

• Competition assays:

  • Perform interaction assays in the presence of competing peptides

  • Use recombinant domains to compete with full-length protein interactions

  • This helps confirm the specificity of observed interactions

• Negative control proteins:

  • Include unrelated proteins as negative controls (e.g., Morc3 has been used as a negative control for PCNA interaction)

  • Use closely related proteins to test specificity

• Subcellular co-localization:

  • Perform immunofluorescence to assess co-localization

  • Use super-resolution microscopy for detailed analysis

  • Calculate co-localization coefficients (e.g., Pearson's or Mander's)

• Functional validation:

  • Disrupt the interaction using mutations or competing peptides

  • Assess functional consequences, such as changes in apoptosis or DNA damage response

  • This confirms the biological relevance of the interaction

These controls and validation steps help ensure that observed SIVA1 protein interactions are specific, reproducible, and biologically meaningful.